Lactococcus lactis Strains for Cardiovascular Health Peptides

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current dairy products do not effectively utilize Lactococcus lactis strains to produce bioactive peptides with antihypertensive and cholesterol-lowering effects, despite their potential for improving cardiovascular health, as these strains have not been tested in vivo for health benefits.

Innovation Solution

Specific Lactococcus lactis strains NRRL B-50571 and NRRL B-50572 are identified for their ability to produce bioactive peptides that reduce arterial blood pressure and lower LDL cholesterol, which can be used in food and pharmaceutical products to improve cardiovascular health.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Lactococcus lactis strains are used to produce bioactive peptides in dairy products, then antihypertensive and cholesterol-lowering effects are achieved, but the strains have not been tested in vivo for health benefits

Engineering Contradiction:

Improvehealth benefitsVSAvoidproduction of bioactive peptides

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent implements in vivo testing in spontaneously hypertensive rats to validate the health benefits of Lactococcus lactis strains. This feedback mechanism confirms that the strains produce bioactive peptides with antihypertensive effects (reducing systolic blood pressure by 20-30 mmHg) and cholesterol-lowering effects, thereby establishing reliability before broader application.

Inventive Principle:

Principle #23Feedback

2Stress or pressure

If ACE-inhibitory drugs are used to reduce high arterial blood pressure, then blood pressure control is achieved, but side effects occur

Engineering Contradiction:

Improvearterial blood pressureVSAvoidside effects

Core Design Contradiction:

Stress or pressureVSObject-affected harmful factors

Solution Approach 1:

The patent uses food-derived bioactive peptides from fermented dairy products as a natural alternative to synthetic ACE-inhibitory drugs. These peptides provide blood pressure control through ACE inhibition without the harmful side effects associated with pharmaceutical interventions, offering a safer long-term solution.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Quantity of substance

If milk proteins are fermented with lactic acid bacteria to increase bioactive peptides, then ACE-inhibitory activity is improved, but the specific strains for LDL cholesterol lowering are not identified

Engineering Contradiction:

Improvebioactive peptidesVSAvoidstrain selection

Core Design Contradiction:

Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent identifies specific local qualities of Lactococcus lactis strains NRRL B-50571 and NRRL B-50572 that enable them to produce bioactive peptides with dual functionality: ACE-inhibitory activity for blood pressure control and cholesterol-lowering effects. This strain-specific selection ensures manufacturing precision for achieving both health benefits.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The bioactive peptides produced by these strains demonstrate significant antihypertensive and hypolipidemic effects in spontaneously hypertensive rats, providing a viable option for reducing blood pressure and improving cardiovascular health without the secondary effects of synthetic drugs.

Implementation Method 1

LAB growth in milk is dependent on the specific proteolytic systems for the generation of free peptides as a source of nitrogen

Methodology Applied

Scientific EffectProteolysis: Hydrolysis

Implementation Method 2

The conversion of angiotensin I into angiotensin II, a potent vasoconstrictor octapeptide, by the angiotensin-converting enzyme (ACE) has long been known. Hence, the inhibition of this enzyme can reduce high arterial blood pressure through ACE-inhibitory (ACEI) compounds.

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 3

Specific Lactococcus lactis strains NRRL B-50571 and NRRL B-50572 have the capacity to produce bioactive peptides that have remarkable capacity to generate an antihypertensive effect in mammals

Methodology Applied

Scientific EffectFermentation: Fermentation

Data Source

PatentUS10864247B2Method for lowering low density lipoproteins

Publication Date: 2020.12.15 CENT DE INVESTIGACION EM ALIMENTACION & DESSAROLO A C

AI summary

New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.